American Olympic runner Nikki Hiltz, who identifies as transgender non-binary, reacted to the International Olympic Committee’s (IOC) policy to bar males from women’s competitions on Friday. The IOC ...

Ritek's warning that geopolitical tensions, petrochemical volatility, and rising manufacturing costs have tightened polycarbonate supplies points to global impacts: recordable optical disc prices are ...

Coinbase is walking a tightrope in the negotiation over the Clarity Act, telling the staffs of U.S. senators that the company is not happy with where the lawmakers landed in their latest compromise, ...

“Python’s Kiss” collects a baker’s dozen stories, nine of which previously have been published in the New Yorker and elsewhere (each is illustrated with a drawing by the author’s daughter, Aza Erdrich ...

The Japan Gold Disc Awards has revealed this year’s winners! This week, the Recording Industry Association of Japan (RIAJ) officially announced the winners of the 40th Japan Gold Disc Awards. Stray ...

March 9 (Reuters) - Derivatives and securities exchange operator Cboe (CBOE.Z), opens new tab said on Monday it plans to launch prediction market contracts offering partial payouts based ‌on the ...

Safety Ahmaad Moses was at the Scouting Combine in Indianapolis last week and he’ll be heading to an operating room this week. Moses’s agent Joe DiBenedetto told Tom Pelissero of NFL Media that his ...

Nasdaq Inc. plans to roll out options contracts that would allow yes-or-no bets on a major stock index, the latest exchange operator to put its own spin on fast-growing prediction markets. The company ...

Disc Medicine develops novel therapeutics targeting hematologic diseases, with a pipeline focused on red blood cell biology, heme biosynthesis, and iron homeostasis. The company operates a ...

NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, with more winter weather ahead, we’re talking not just about sore backs but stiff necks. Should you apply heat or ice? And how to know if you ...

Disc Medicine faces a regulatory setback as the FDA issued a CRL for bitopertin, citing insufficient clinical benefit evidence despite clear biomarker reduction. The upcoming Phase 3 APOLLO trial, ...